You are here

  • Home
  • Archive
  • Volume 78, Issue Suppl 2
  • FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL

Citation Tools

Article menu

Download PDFPDF

Poster Presentations
Friday, 14 June 2019
SLE, Sjögren’s and APS – treatment
FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Furie R, Bomba D, Dall’era M, et al
FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL
Annals of the Rheumatic Diseases 2019;78:776-777.